Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198055 · ClinicalTrials.gov registry record · Phase 2
A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00198055 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 25 participants.
The verdict
NCT00198055, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder. We hypothesize that aripiprazole will be effective for reducing aggression and repetitive behavior.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198055
The ClinicalTrials.gov registry entry for NCT00198055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00198055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198055 about?
NCT00198055 is a clinical study titled "A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.". The purpose of this study is to develop a better tolerated and more effective pharmacologic treatment for individuals with Asperger's Disorder and Pervasive Developmental Disorder. This is an open-label investigation of aripiprazole in the management of the maladaptive behaviors of autistic disorder...
What is the current status of trial NCT00198055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2005-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00198055?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00198055?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.